Literature DB >> 10097037

Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

H L Weiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10097037      PMCID： PMC34268          DOI： 10.1073/pnas.96.7.3333

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  49 in total

1.  Immunogenic potentials of copolymer I in normal human lymphocytes.

Authors:  C F Brosnan; M Litwak; P A Neighbour; W D Lyman; T H Carter; M B Bornstein; B R Bloom
Journal:  Neurology       Date:  1985-12       Impact factor: 9.910

2.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

Authors:  R Aharoni; D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 3.  Control of immune pathology by regulatory T cells.

Authors:  D Mason; F Powrie
Journal:  Curr Opin Immunol       Date:  1998-12       Impact factor: 7.486

4.  Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.

Authors:  M L Barnett; J M Kremer; E W St Clair; D O Clegg; D Furst; M Weisman; M J Fletcher; S Chasan-Taber; E Finger; A Morales; C H Le; D E Trentham
Journal:  Arthritis Rheum       Date:  1998-02

5.  In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis.

Authors:  C Webb; D Teitelbaum; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

6.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

7.  Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.

Authors:  D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

8.  Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids.

Authors:  C Webb; D Teitelbaum; A Herz; R Arnon; M Sela
Journal:  Immunochemistry       Date:  1976-04

9.  Human cellular immune response to copolymer I and myelin basic protein.

Authors:  J Burns; L J Krasner; F Guerrero
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

10.  Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

Authors:  A Miller; S Shapiro; R Gershtein; A Kinarty; H Rawashdeh; S Honigman; N Lahat
Journal:  J Neuroimmunol       Date:  1998-12-01       Impact factor: 3.478
View more
  10 in total

1.  Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis.

Authors:  H L Weiner
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Oral tolerance, an active immunologic process mediated by multiple mechanisms.

Authors:  H L Weiner
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 3.  CD40L in autoimmunity and mucosally induced tolerance.

Authors:  Mi-Na Kweon; Hiroshi Kiyono
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 4.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

5.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

Authors:  O Neuhaus; C Farina; A Yassouridis; H Wiendl; F Then Bergh; T Dose; H Wekerle; R Hohlfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

7.  Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.

Authors:  B Fellay; M Chofflon; C Juillard; A M Paunier; T Landis; S Roth; M L Gougeon
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 8.  Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?

Authors:  Henry Yim Wu
Journal:  Clin Immunol       Date:  2008-10-19       Impact factor: 3.969

Review 9.  Oral tolerance.

Authors:  Henry Yim Wu; Howard L Weiner
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

10.  Glatiramer acetate attenuates the activation of CD4+ T cells by modulating STAT1 and -3 signaling in glia.

Authors:  Ye-Hyeon Ahn; Sae-Bom Jeon; Chi Young Chang; Eun-Ah Goh; Sang Soo Kim; Ho Jin Kim; Jaewhan Song; Eun Jung Park
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.